CRISPR-CAS COMPONENT SYSTEMS, METHODS AND COMPOSITIONS FOR SEQUENCE MANIPULATION
The invention provides for systems, methods, and compositions for manipulation of sequences and/or activities of target sequences. Provided are vectors and vector systems, some of which encode one or more components of a CRISPR complex, as well as methods for the design and use of such vectors. Also provided are methods of directing CRISPR complex formation in eukaryotic cells and methods for selecting specific cells by introducing precise mutations utilizing the CRISPR/Cas system.
1 . An ex vivo human cell comprising:
(i) a Cas9 comprising one or more nuclear localization signals,
(ii) a first RNA sequence with a sequence complementary to a target sequence within a beta-2-microglobulin (B2M) gene, wherein the first RNA sequence also comprises a tracr-mate sequence,
(ii) a second RNA sequence comprising a sequence complementary to the tracr-mate sequence,
wherein the first RNA sequence and the second RNA sequence are in a chimeric RNA,
wherein the Cas9 is complexed with the chimeric RNA, and
wherein the chimeric RNA and the Cas9 do not occur naturally together.
2 . The ex vivo human cell of claim 1 , wherein at least one nuclear localization signal is a SV40 large T-antigen nuclear localization signal.
3 . The ex vivo human cell of claim 2 , wherein the one or more nuclear localization signals are at the C-terminus of the Cas9 and/or at the N-terminus of the Cas9.
4 . The ex vivo human cell of claim 2 , wherein the Cas9 is flanked on each end by at least one nuclear localization signal.
5 . The ex vivo human cell of claim 2 , wherein the SV40 large T-antigen nuclear localization signal comprises the sequence PKKKRKV (SEQ ID NO:1).
6 . The ex vivo human cell of claim 1 , wherein the Cas9 is an S. pyogenes Cas9.
7 . The ex vivo human cell of claim 1 , wherein the sequence complementary to the target sequence is between 15-25 nucleotides in length.
8 . The ex vivo human cell of claim 1 , wherein the tracr-mate sequence comprises the sequence GUUUUAGAGCUA (SEQ ID NO: 30).
9 . The ex vivo human cell of claim 1 , wherein the first RNA sequence comprises one or more methylated nucleotides.
10 . The ex vivo human cell of claim 1 , wherein the second RNA sequence comprises one or more methylated nucleotides.
11 . The ex vivo human cell of claim 1 , wherein the target sequence comprises a coding sequence.
12 . The ex vivo human cell of claim 1 , further comprising a homologous recombination (HR) template for targeted gene insertion.
13 . The ex vivo human cell of claim 1 , wherein the cell is an embryonic stem cell.
14 . An ex vivo human cell comprising:
(i) an S. pyogenes Cas9 comprising one or more nuclear localization signals,
(ii) a first RNA sequence comprising a sequence complementary to a target sequence within a B2M gene, wherein the first RNA sequence also comprises a tracr-mate sequence,
(ii) a second RNA sequence comprising a sequence complementary to the tracr-mate sequence,
wherein the first RNA sequence and the second RNA sequence are in a chimeric RNA,
wherein the Cas9 is complexed with the chimeric RNA, and
wherein the chimeric RNA and the Cas9 do not occur naturally together.
15 . The ex vivo human cell of claim 14 , wherein at least one nuclear localization signal is a SV40 large T-antigen nuclear localization signal, wherein the SV40 large T-antigen nuclear localization signal comprises the sequence PKKKRKV (SEQ ID NO: 1).
16 . The ex vivo human cell of claim 14 , wherein the one or more nuclear localization signals are at the C-terminus of the S. pyogenes Cas9 and/or at the N-terminus of the S. pyogenes Cas9.
17 . The ex vivo human cell of claim 14 , wherein the S. pyogenes Cas9 is flanked on each end by at least one nuclear localization signal.
18 . The ex vivo human cell of claim 14 , wherein the sequence complementary to the target sequence is between 15-25 nucleotides in length.
19 . The ex vivo human cell of claim 14 , wherein the tracr-mate sequence comprises the sequence GUUUUAGAGCUA (SEQ ID NO: 30).
20 . The ex vivo human cell of claim 14 , wherein the first RNA sequence comprises one or more methylated nucleotides.
21 . The ex vivo human cell of claim 14 , wherein the second RNA sequence comprises one or more methylated nucleotides.
22 . The ex vivo human cell of claim 14 , wherein the target sequence comprises a coding sequence.
23 . The ex vivo human cell of claim 14 , further comprising a HR template for targeted gene insertion.
24 . An ex vivo human cell comprising:
(i) an S. pyogenes Cas9 comprising one or more nuclear localization signals,
(ii) a first RNA sequence comprising a sequence complementary to a target sequence within a B2M gene,
wherein the first RNA sequence comprises one or more methylated nucleotides,
wherein the first RNA sequence comprises a tracr-mate sequence that comprises the sequence GUUUUAGAGCUA (SEQ ID NO: 30), and
(ii) a second RNA sequence comprising a sequence complementary to the tracr-mate sequence,
wherein the second RNA sequence comprises one or more methylated nucleotides,
wherein the first RNA sequence and the second RNA sequence are in a chimeric RNA,
wherein the Cas9 is complexed with the chimeric RNA, and
wherein the chimeric RNA and the Cas9 do not occur naturally together.
25 . The ex vivo human cell of claim 24 , wherein at least one nuclear localization signal is a SV40 large T-antigen nuclear localization signal, wherein the SV40 large T-antigen nuclear localization signal comprises the sequence PKKKRKV (SEQ ID NO: 1).
26 . The ex vivo human cell of claim 24 , wherein the target sequence comprises a coding sequence.
27 . The ex vivo human cell of claim 24 , further comprising a HR template for targeted gene insertion.
28 . The ex vivo human cell of claim 24 , wherein the cell is an embryonic stem cell.
29 . The ex vivo human cell of claim 24 , wherein the one or more nuclear localization signals are at the C-terminus of the S. pyogenes Cas9 and/or at the N-terminus of the S. pyogenes Cas9.
30 . The ex vivo human cell of claim 24 , wherein the S. pyogenes Cas9 is flanked on each end by at least one nuclear localization signal.